Long-term data buffers Wegovy

Posted 15 May 2024 AM

New data from the largest and longest clinical trial of semaglutide on weight loss have affirmed the longevity and safety of the drug over four years.

The data from the 17,000 person Semaglutide and Cardiovascular Outcomes (SELECT) trial, presented at the European Congress on Obesity this week, showed that people taking semaglutide lost on average 10.2 per cent of their body weight and 7.7 cm from their waistline, compared with 1.5 per cent of weight and 1.3 cm of waistline for the placebo group.

To see the whole article, please login